Menstrual blood loss Menstruation "more abundant than normal" (questionnaire)
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Menstruation "more painful than normal"
It is very uncertain whether interventions (ibuprofen, tolfenamic acid) changes menstruation "more painful than normal" compared with placebo (very low certainty).
1 finding from 1 review
Depression (6 months or more) MADRS measured 6 months after intervention (Aljumah 2015). PHQ‐9 measured 6 months after intervention (LeBlanc 2015). QIDS‐J measured 6 months after intervention (Aoki 2019a). Hospital Anxiety and Depression Scale (HA... · patients with mental health disorders
1 finding from 1 review
Patient readmissions · patients with mental health disorders
It is very uncertain whether shared decision‐making interventions changes readmission (6 months or more) Rehospitalisation at 8 months after… compared with usual care (very low certainty).
1 finding from 1 review
CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy
Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with placebo (very low certainty).
1 finding from 1 review
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Palpebral aperture improvement (decrease) by 3 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes CAS improvement (decrease) by 2 or more points compared with placebo (very low certainty).
1 finding from 1 review
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 classes or more compared with placebo (very low certainty).
1 finding from 1 review
Systolic blood pressure. Dose 1500 mg a day or more (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Number of people who experienced 1 or more admissions to a nursing care facility · older people living in the community with frailty
1 finding from 1 review
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · children and adults with SCD and PSR
1 finding from 1 review
Measurable change in stereopsis after 8 (± 2) weeks and 16 (± 2) weeks of intervention 'Real change' in stereopsis is defined as a change in stereoacuity of two or more octaves. · 5‐ to 8‐year‐old children with amblyopia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of people who experienced one or more falls · people with Parkinson's disease
It is very uncertain whether summary of findings for education changes number of people who experienced one or more falls compared with control (very low certainty).
1 finding from 1 review
Number of people sustaining one or more fall‐related fractures · people with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of people who experienced one or more falls · people with Parkinson's disease
Summary of findings for exercise showed no clear difference in number of people who experienced one or more falls compared with control (moderate certainty).
1 finding from 1 review
Number of people who experienced one or more falls · people with Parkinson's disease
Summary of findings for exercise plus education showed no clear difference in number of people who experienced one or more falls compared with control (low certainty).
1 finding from 1 review